We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Refinitiv and Factset).
We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.
Published reports can be obtained by searching our Research Library below, or directly from our Featured Companies page.
HUTCHMED
First ATTC deal: GSK $110m upfront for KRAS/EGFROxford BioDynamics
£9m raise gives management time to enact strategyHUTCHMED
SAFFRON data positions savo combo competitivelyHUTCHMED
H126: China recovery and Fruzaqla drive sales growthScancell
Strategic transactions to unlock longer-term valueAvacta
Tumour-activated drug delivery demonstratedOxford BioDynamics
H126: encouraging progress but challenges remainScancell
iSCIB1+ pivotal trial plans advancingHUTCHMED
ATTC data confirms clinical potentialAvacta
Raise of £9m pays down convertible bond to c £11.5m